查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1618546

腰椎间盘退化性疾病市场：治疗方法、给药途径和最终用户分类 - 全球预测 2025-2030

Lumbar Degenerative Disc Disease Market by Treatment (Epidural Steroid Injections (ESIs), Over-the-counter (OTC) Pain Medications, Therapy Devices), Route of Administration (Injectables, Oral), End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

腰椎退化性疾病市场价值2023年为7.4458亿美元，预计到2024年将达到7.9633亿美元，复合年增长率为7.15%，到2030年预计将达到12.0776亿美元。

腰椎退化性疾病（LDDD）是一种以腰椎间盘劣化为特征的疾病，导致慢性疼痛。这种疾病在老年人和久坐人群中的盛行率不断增加，增加了对有效治疗方法和技术的需求。市场范围包括外科介入、生物疗法以及再生医学和微创手术等新技术解决方案。背部和颈部疼痛是就医和缺勤的首要原因之一，推动了从医院到门诊手术中心等医疗领域的应用。对个人化和具有成本效益的治疗的需求正在进一步指导最终用途，重点是以患者为中心的护理模式。关键的成长要素包括脊椎设备和再生医学的技术进步、医疗保健支出的增加以及患者对可用治疗方法的认识的提高。治疗机会在于采用再生疗法，例如创新的生物材料和基于干细胞的产品，这些产品具有侵入性较小且有效的治疗潜力。开发商应利用推广非手术治疗来缓解疼痛和阻止疾病进展的趋势，同时扩大其在医疗基础设施快速发展的新兴市场的地理影响力。相反，市场成长的限制包括高昂的手术成本和与新医疗技术相关的监管复杂性。来自物理疗法和脊骨神经医学等替代疗法的竞争也可能是一个挑战。需要创新的领域包括开发下一代生技药品、用于更好诊断的先进成像以及用于连续监测的患者友好型可穿戴技术。公司应该投资研究合作和病患教育，以提高对新治疗方法的接受度。该市场本质上仍然充满活力，由于新进入者的强大管道以及技术进步和全球人口老化导致的需求增加，具有巨大的成长空间。

主要市场统计
基准年[2023] 74458万美元
预计年份 [2024] 7.9633亿美元
预测年份 [2030] 1,207.76 百万美元
复合年增长率（%） 7.15%

市场动态：揭示快速发展的腰椎退化性疾病市场的关键市场洞察

腰椎退化性疾病市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 腰椎间盘退化性疾病的盛行率不断扩大
    • 进行宣传活动并加强有关 LDDD 的教育
  • 市场限制因素
    • 报销限制
  • 市场机会
    • 持续研究和开发引入新的 LDDD 治疗和诊断
    • 政府对 LDDD 治疗商业化的有利核准
  • 市场问题
    • 手术和药物开发的复杂性

波特五力：驾驭腰椎退化性疾病市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解腰椎退化性疾病市场的外部影响

外部宏观环境因素在塑造腰椎退化性疾病市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解腰椎间盘退化性疾病市场的竞争格局

腰椎间盘退化性疾病市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 定位矩阵：腰椎间盘退化性疾病市场供应商的绩效评估

FPNV 定位矩阵是评估腰椎退化性疾病市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製腰椎退化性疾病市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对腰椎退化性疾病市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争格局中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境，主要企业的广泛资料，评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、主要产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

它也回答重要问题，帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 腰退化性疾病的盛行率不断增加
      • 扩大 LDDD 的宣传活动和教育
    • 抑制因素
      • 退款数量有限
    • 机会
      • 持续研究和开发，为 LDDD 引入新的治疗方法和诊断方法
      • 政府对 LDDD 药物商业化的有利核准
    • 任务
      • 手术和药物开发的复杂性
  • 市场区隔分析
    • 治疗：增加使用硬膜外类固醇注射 (ESI) 来治疗腰椎退化性疾病
    • 最终用户：对腰椎退化性疾病治疗的患者诊断、治疗和管理的需求不断增加
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章腰椎间盘退化性疾病市场：依治疗分类

  • 介绍
  • 硬脊膜外类固醇注射 (ESI)
  • 非处方止痛药
    • 乙酰胺酚
    • 抗发炎药
    • 皮质类固醇
    • 肌肉鬆弛剂
    • 药品
  • 治疗设备

第七章腰椎间盘退化性疾病市场：依给药途径

  • 介绍
  • 注射
  • 口服

第八章腰椎间盘退化性疾病市场：依最终用户分类

  • 介绍
  • 学术研究中心
  • 医院/诊所
  • 专科诊所

第九章北美及南美腰退化性疾病市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区腰椎间盘退化性疾病市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东与非洲腰椎间盘退化性疾病市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FDA核准ReGelTec 的 HYDRAFIL 系统用于治疗腰椎退化性疾病
    • RIT 研究人员获得 NIH津贴，用于 CRISPR 增强干细胞疗法治疗腰椎退化性疾病
    • Companion Spine 透过策略收购 Backbone SAS 推动全球脊椎医学发展
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AnGes MG, Inc.
  • AxioMed LLC
  • B. Braun SE
  • Baxter International Inc.
  • Benvenue Medical, Inc.
  • Biopharm GmbH
  • Boston Scientific Corporation
  • Centinel Spine, LLC
  • Cerapedics Inc.
  • ChoiceSpine
  • DePuy Synthes by Medical Device Business Services, Inc.
  • Globus Medical, Inc.
  • Kolon TissueGene Inc.
  • Kuros Biosciences
  • Lineage Cell Therapeutics, Inc.
  • Medtronic plc
  • NLC Ventures Netherlands BV
  • Notogen, Inc.
  • Orthofix Medical Inc.
  • RTI Surgical Holdings, Inc.
  • Stryker Corporation
  • Ulrich Medical USA Inc.
  • Veritas Health, LLC
  • Xtant Medical Holdings, Inc.
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-D566A980152E

The Lumbar Degenerative Disc Disease Market was valued at USD 744.58 million in 2023, expected to reach USD 796.33 million in 2024, and is projected to grow at a CAGR of 7.15%, to USD 1,207.76 million by 2030.

Lumbar Degenerative Disc Disease (DDD) is a condition characterized by the deterioration of the intervertebral discs in the lumbar spine, causing chronic pain. The rising prevalence of this ailment among aging populations and sedentary individuals propels demand for effective treatments and technologies. The market scope encompasses surgical interventions, biological therapies, and emerging technology-based solutions like regenerative medicine and minimally invasive procedures. A significant necessity drives this market; back and neck pain is among the top reasons for physician visits and absenteeism from work, fostering applications in healthcare sectors from hospitals to outpatient surgical centers. The need for personalized, cost-effective treatments further guides end-use by focusing on patient-centric care models. Key growth factors include technological advancements in spinal devices and regenerative medicine, increasing healthcare expenditures, and growing awareness of available treatments among patients. Opportunities lie in the adoption of innovative biomaterials and regenerative therapies, like stem cell-based products, which show potential for less invasive and more effective treatments. Commercial entities should capitalize on trends promoting non-surgical therapies designed to alleviate pain and halt the disease's progression while broadening their geographical presence in emerging markets where healthcare infrastructure is developing rapidly. Conversely, market growth constraints include high procedure costs and the regulatory complexities associated with new medical technologies. Competition from alternative treatments such as physical therapy and chiropractic interventions may also pose challenges. Areas ripe for innovation include the development of next-generation biologics, advanced imaging for better diagnosis, and patient-friendly, wearable technologies for continuous monitoring. Businesses should invest in research partnerships and patient education to foster acceptance of novel therapies. The market maintains a dynamic nature with a robust pipeline for new entrants and substantial room for growth, driven by both technological advancements and a demand increase prompted by an aging global population.

KEY MARKET STATISTICS
Base Year [2023] USD 744.58 million
Estimated Year [2024] USD 796.33 million
Forecast Year [2030] USD 1,207.76 million
CAGR (%) 7.15%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Lumbar Degenerative Disc Disease Market

The Lumbar Degenerative Disc Disease Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of lumbar degenerative disc disease
    • Rising awareness campaigns and education about LDDD
  • Market Restraints
    • Limited availability of reimbursement
  • Market Opportunities
    • Ongoing R&D for introducing new LDDD treatments and diagnosis
    • Favorable government approvals for LDDD medicine commercialization
  • Market Challenges
    • Complexity in surgical procedures and medicine development

Porter's Five Forces: A Strategic Tool for Navigating the Lumbar Degenerative Disc Disease Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Lumbar Degenerative Disc Disease Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Lumbar Degenerative Disc Disease Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Lumbar Degenerative Disc Disease Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Lumbar Degenerative Disc Disease Market

A detailed market share analysis in the Lumbar Degenerative Disc Disease Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Lumbar Degenerative Disc Disease Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Lumbar Degenerative Disc Disease Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Lumbar Degenerative Disc Disease Market

A strategic analysis of the Lumbar Degenerative Disc Disease Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lumbar Degenerative Disc Disease Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AnGes MG, Inc., AxioMed LLC, B. Braun SE, Baxter International Inc., Benvenue Medical, Inc., Biopharm GmbH, Boston Scientific Corporation, Centinel Spine, LLC, Cerapedics Inc., ChoiceSpine, DePuy Synthes by Medical Device Business Services, Inc., Globus Medical, Inc., Kolon TissueGene Inc., Kuros Biosciences, Lineage Cell Therapeutics, Inc., Medtronic plc, NLC Ventures Netherlands B.V., Notogen, Inc., Orthofix Medical Inc., RTI Surgical Holdings, Inc., Stryker Corporation, Ulrich Medical USA Inc., Veritas Health, LLC, Xtant Medical Holdings, Inc., and Zimmer Biomet Holdings, Inc..

Market Segmentation & Coverage

This research report categorizes the Lumbar Degenerative Disc Disease Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Epidural Steroid Injections (ESIs), Over-the-counter (OTC) Pain Medications, and Therapy Devices. The Over-the-counter (OTC) Pain Medications is further studied across Acetaminophen, Anti-inflammatories, Corticosteroids, Muscle Relaxants, and Narcotics.
  • Based on Route of Administration, market is studied across Injectables and Oral.
  • Based on End-Users, market is studied across Academic Research Centers, Hospitals & Clinics, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of lumbar degenerative disc disease
      • 5.1.1.2. Rising awareness campaigns and education about LDDD
    • 5.1.2. Restraints
      • 5.1.2.1. Limited availability of reimbursement
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D for introducing new LDDD treatments and diagnosis
      • 5.1.3.2. Favorable government approvals for LDDD medicine commercialization
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in surgical procedures and medicine development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Rising usage of epidural steroid injections (ESIs) for management of lumbar degenerative disc disease
    • 5.2.2. End-Users: Increasing need for lumbar degenerative disc disease treatment for diagnosing, treating, and managing patients
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Lumbar Degenerative Disc Disease Market, by Treatment

  • 6.1. Introduction
  • 6.2. Epidural Steroid Injections (ESIs)
  • 6.3. Over-the-counter (OTC) Pain Medications
    • 6.3.1. Acetaminophen
    • 6.3.2. Anti-inflammatories
    • 6.3.3. Corticosteroids
    • 6.3.4. Muscle Relaxants
    • 6.3.5. Narcotics
  • 6.4. Therapy Devices

7. Lumbar Degenerative Disc Disease Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectables
  • 7.3. Oral

8. Lumbar Degenerative Disc Disease Market, by End-Users

  • 8.1. Introduction
  • 8.2. Academic Research Centers
  • 8.3. Hospitals & Clinics
  • 8.4. Specialty Clinics

9. Americas Lumbar Degenerative Disc Disease Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Lumbar Degenerative Disc Disease Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Lumbar Degenerative Disc Disease Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. FDA Clears ReGelTec's HYDRAFIL System for Treatment of Lumbar Degenerative Disc Disease
    • 12.3.2. RIT Researchers Awarded NIH Grant to CRISPR-Enhanced Stem Cell Therapy for Lumbar Degeneration
    • 12.3.3. Companion Spine Advances Global Spine Health with Strategic Acquisition of Backbone SAS
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AnGes MG, Inc.
  • 3. AxioMed LLC
  • 4. B. Braun SE
  • 5. Baxter International Inc.
  • 6. Benvenue Medical, Inc.
  • 7. Biopharm GmbH
  • 8. Boston Scientific Corporation
  • 9. Centinel Spine, LLC
  • 10. Cerapedics Inc.
  • 11. ChoiceSpine
  • 12. DePuy Synthes by Medical Device Business Services, Inc.
  • 13. Globus Medical, Inc.
  • 14. Kolon TissueGene Inc.
  • 15. Kuros Biosciences
  • 16. Lineage Cell Therapeutics, Inc.
  • 17. Medtronic plc
  • 18. NLC Ventures Netherlands B.V.
  • 19. Notogen, Inc.
  • 20. Orthofix Medical Inc.
  • 21. RTI Surgical Holdings, Inc.
  • 22. Stryker Corporation
  • 23. Ulrich Medical USA Inc.
  • 24. Veritas Health, LLC
  • 25. Xtant Medical Holdings, Inc.
  • 26. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. LUMBAR DEGENERATIVE DISC DISEASE MARKET RESEARCH PROCESS
  • FIGURE 2. LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. LUMBAR DEGENERATIVE DISC DISEASE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. LUMBAR DEGENERATIVE DISC DISEASE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LUMBAR DEGENERATIVE DISC DISEASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LUMBAR DEGENERATIVE DISC DISEASE MARKET DYNAMICS
  • TABLE 7. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY EPIDURAL STEROID INJECTIONS (ESIS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ACETAMINOPHEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY MUSCLE RELAXANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY NARCOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY THERAPY DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ACADEMIC RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY OVER-THE-COUNTER (OTC) PAIN MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM LUMBAR DEGENERATIVE DISC DISEASE MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 192. LUMBAR DEGENERATIVE DISC DISEASE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. LUMBAR DEGENERATIVE DISC DISEASE MARKET, FPNV POSITIONING MATRIX, 2023